Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder.


Journal

Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909

Informations de publication

Date de publication:
03 2022
Historique:
received: 22 12 2020
revised: 06 05 2021
accepted: 14 06 2021
pubmed: 3 7 2021
medline: 22 3 2022
entrez: 2 7 2021
Statut: ppublish

Résumé

Several factors may influence the validity of self-report. In this study, we aimed to assess the validity of self-reported drug use compared to urine testing among treatment-seeking patients with opioid use disorder (OUD). This cross-sectional study recruited 293 patients with OUD, referred to the Iranian National Center for Addiction Studies (INCAS) clinic, from November 2015 to June 2017. The study compared self-reported opioid use in the past 72 h with the results of urinalysis, using immunoassay technique. We estimated sensitivity, negative predictive value, percent agreement, positive percent agreement, and Cohen's kappa statistics for those with OUD. The sensitivity of self-reported opioid use was 85.9%. Percent agreement, positive percent agreement, and Cohen's Kappa statistics between self-reported opioid use and urine testing for morphine in the first month were 88.5%, 78.1%, and 77.0, respectively. Multilevel logistic regression showed that longer treatment duration (OR = 1.21, 95%CI: 1.07-1.37, p-value = 0.002) was significantly associated with the agreement of self-reported opioid use with urine testing. Self-report can be used as a reliable method for monitoring treatment adherence combined with random urine tests.

Sections du résumé

BACKGROUND
Several factors may influence the validity of self-report. In this study, we aimed to assess the validity of self-reported drug use compared to urine testing among treatment-seeking patients with opioid use disorder (OUD).
METHODS
This cross-sectional study recruited 293 patients with OUD, referred to the Iranian National Center for Addiction Studies (INCAS) clinic, from November 2015 to June 2017. The study compared self-reported opioid use in the past 72 h with the results of urinalysis, using immunoassay technique. We estimated sensitivity, negative predictive value, percent agreement, positive percent agreement, and Cohen's kappa statistics for those with OUD.
RESULTS
The sensitivity of self-reported opioid use was 85.9%. Percent agreement, positive percent agreement, and Cohen's Kappa statistics between self-reported opioid use and urine testing for morphine in the first month were 88.5%, 78.1%, and 77.0, respectively. Multilevel logistic regression showed that longer treatment duration (OR = 1.21, 95%CI: 1.07-1.37, p-value = 0.002) was significantly associated with the agreement of self-reported opioid use with urine testing.
CONCLUSION
Self-report can be used as a reliable method for monitoring treatment adherence combined with random urine tests.

Identifiants

pubmed: 34210569
pii: S0740-5472(21)00281-6
doi: 10.1016/j.jsat.2021.108555
pii:
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108555

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Behrang Shadloo (B)

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, No. 486, South Karegar Ave., Tehran 1336616357, Iran. Electronic address: behrang.shadloo@gmail.com.

Shahab Baheshmat (S)

Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: shahab.baheshmat@gmail.com.

Yasna Rostam-Abadi (Y)

Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: y-rostamabadi@student.tums.ac.ir.

Atena Shakeri (A)

Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: ati.shakeri@yahoo.com.

Jaleh Gholami (J)

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, No. 486, South Karegar Ave., Tehran 1336616357, Iran. Electronic address: zh_gholami@farabi.tums.ac.ir.

Afarin Rahimi-Movaghar (A)

Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: rahimia@tums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH